Optimizing Bioassays for Biologics

Optimizing Bioassays for Biologics will bring together speakers from industry and academia working in bioassay development, bioprocessing, and bioanalytical. Here the aim has been educating newer and up-and-coming scientists entering this field in large numbers, showcasing cutting edge and case studies from their work, and discussing how regulatory agencies in the US and in Europe are viewing testing with emerging modalities, especially with cell and gene therapy. Participate to hear from innovative speakers, especially those with a product coming to market, on best practices for handling the most common challenges in biological assay development, validation, transfer, and maintenance. How did they get a product to market in the face of challenges like creating a standard, how did they deal with potency calculations, and beyond.

Speakers (past edition)

Speaker

Karl Griswold

Associate Professor at Thayer School of Engineering at Dartmouth... United States

Follow

Speaker

Ronit Mazor, Ph.D.

Postdoctoral Research Fellow at National Cancer Institute (NCI) Washington DC, United States

Follow

Speaker

David Wraith

Professor of Experimental Pathology, University of Bristol at University of... Bristol, United Kingdom

Follow

Speaker

Baolin Zhang

Senior Investigator at U.S. Department of Health and Human Services United States

Follow

Speaker

Stephen DeWall

Principal Scientist, Clinical Immunology at GlaxoSmithKline United States

Follow

Speaker

Martin Gleeson

Chief Scientific Officer at Genalyte, Inc United States

Follow

Follow
More Speakers